Nano-X Imaging Ltd. Stock Price, News & Analysis

NANO-X IMAGING LTD (NNOX) has announced a new CPT code from the American Medical Association for its HealthCCSng AI-enabled cardiac imaging solution, effective July 1, 2022. This code promotes the use of AI for detecting coronary artery calcium, a key indicator of cardiovascular disease, enhancing early detection and treatment opportunities. The code aims to streamline workflows for U.S. radiologists and improve patient care. The company has previously secured recognition for AI in imaging, indicating significant progress in medical technology.

NANO-X IMAGING LTD. (NNOX) announced that its subsidiary, USARAD Holdings, Inc., received re-certification from The Joint Commission with the Gold Seal of Approval. This certification underscores USARAD's commitment to high-quality and safe patient care, achieving compliance without conditions in an unannounced inspection. With a robust network of board-certified teleradiologists, USARAD aims to address the global radiologist shortage by integrating AI technology to enhance its imaging services. The company operates under an accelerating demand for outsourced imaging solutions.

NANO-X IMAGING LTD (NASDAQ: NNOX) will conduct a virtual tour of its Nanox.ARC at the RSNA Annual Meeting on December 1, 2021, at 11:30 am EST. The tour will be followed by an investor webinar at 2:00 pm EST the same day. This event will showcase the Nanox.ARC in a clinical setting from Shamir Medical Center, Israel. Interested participants can register for the meeting and will have access to a replay and Q&A session during the webinar.

For more details, visit www.nanox.vision.

NANO-X IMAGING LTD (NASDAQ: NNOX) reported its Q3 2021 results, ending the period with cash and marketable securities of $180.3 million. The company experienced a net loss of $13.5 million, up from $11.1 million in Q3 2020, primarily due to increased R&D and administrative expenses. Highlights include the completion of the Nanox AI merger and acquisitions of USARAD Holdings and MDWEB, aimed at enhancing its imaging technology and analytics capabilities. The company has signed MSaaS agreements for 6,500 Nanox.ARC units and expects to commercialize its technology in 2022.

NANO-X IMAGING LTD (NASDAQ: NNOX) announced its participation in the 2021 Radiology Society of North America (RSNA) Annual Meeting from Nov. 28 to Dec. 2. Key highlights include the debut of the Nanox.ARC procedures at their virtual booth and a showcase of AI-enabled medical imaging solutions at booth 4949. A virtual tour from Shamir Medical Center will occur on Dec. 1 at 10:30 am CST. These advancements aim to enhance affordability and accessibility in medical imaging, aligning with their goal of improving early detection services.

NANO-X IMAGING LTD (NASDAQ: NNOX) has completed its merger with Zebra Medical Vision, Ltd., valued at approximately $110 million, with additional stock options worth up to $84 million contingent on performance milestones. The Company also acquired MDWEB, LLC and USARAD Holdings, Inc. for around $20 million in stock and cash, with potential additional payments of $10 million. These strategic acquisitions aim to enhance Nanox's AI-powered imaging solutions, addressing the global shortage of radiologists and improving healthcare delivery.

NANO-X IMAGING LTD (NNOX) is set to report its third-quarter results for the period ending September 30, 2021, on November 17, 2021, before market opening. Ran Poliakine, the CEO, along with Erez Meltzer, the newly appointed CEO effective January 1, 2022, will lead a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can join via phone or webcast. Nanox aims to transform medical imaging with its innovative digital X-ray technology.

NANO-X IMAGING LTD (NNOX) has partnered with International Clinics Group to enhance medical imaging accessibility in Chile, Bolivia, and Peru. This collaboration aims to deploy the Nanox System, which includes the Nanox.ARC imaging device and Nanox.CLOUD services, across various healthcare facilities, subject to regulatory approval. The initiative addresses the shortage of medical imaging in rural areas, where access is limited. The World Health Organization indicates that two-thirds of the global population lacks adequate imaging services, emphasizing the need for such advancements.

NANO-X IMAGING (NNOX) announced the 8th FDA clearance for its Coronary Artery Calcium solution, enhancing its population health offerings via Zebra Medical Vision. This follows a merger agreement with Zebra aimed at expanding AI-based diagnostic capabilities for chronic conditions. Nanox aims to revolutionize medical imaging with its digital X-ray technology, potentially lowering costs and improving access to early detection services. The company highlights risks linked to acquisitions and regulatory clearances in its forward-looking statements.